Browse the evidence

Consumers currently taking a GLP-1 consume significantly fewer calories than the other groups surveyed, with calorie reduction while taking a GLP-1 for weight loss estimated to be around 720 to 990 calories.

Practitioners should consider that GLP-1 users may have lower caloric intake, which could influence dietary recommendations.

GLP-1 users most likely reduce consumption of processed foods, sugar-sweetened beverages, refined grains, and beef.

Dietitians may need to adjust food recommendations for patients using GLP-1 based on their reduced consumption of certain food types.

Individuals in the Persistent+GLP-1 naive cohort achieved a mean weight reduction of 12.9% at 6-months post-index.

Practitioners can expect significant weight loss in eligible patients using tirzepatide over a 6-month period.

High ultraprocessed food (UPF) intake is consistently linked to negative health outcomes.

Practitioners should be aware of the negative health implications of high UPF consumption.

Food policies that limit UPF intake are supported by evidence.

Policymakers should consider implementing regulations to reduce UPF consumption.

Weight loss reduces the recurrence of symptomatic atrial fibrillation.

Weight management should be a focus in the treatment plan for patients with AF.

Oral semaglutide, 50 mg, led to a mean percentage change in body weight of -14.3% compared to -1.3% with placebo.

Oral semaglutide is effective for significant weight loss in this population.

84.3% of participants on semaglutide achieved a 5% or greater body weight reduction compared to 17.2% on placebo.

A high proportion of patients on semaglutide can expect significant weight loss.

R-ESG offered higher total body weight loss (TBWL%) than GLP1/GIP-RA at 3 months (11.2% vs. 4.3%, p < .001), 6 months (13.5% vs. 6.8%, p < .001), and 12 months (13.4% vs. 9.2%, p = .07).

Practitioners may consider R-ESG as a more effective option for weight loss in patients experiencing weight recidivism after sleeve gastrectomy.

GLP1/GIP-RA achieved significantly lower TBWL% in patients with prior SG compared to those with intact stomach at 3 months (4.3% vs. 5.7%, p = .02), 6 months (6.8% vs. 9.2%, p = .02), and 12 months (9.2% vs. 12.7%, p = .03).

Practitioners should be aware that GLP1/GIP-RA may be less effective for weight loss in patients with prior sleeve gastrectomy compared to those with intact stomachs.

Energy intake of the slow-ER/low-ED meal was 573 kcal (50%) lower compared to the fast-ER/high-ED meal.

Practitioners should consider the impact of meal energy density and eating rate on energy intake when designing meal plans.

A slow-ER and low-ED reduced energy intake by 59% compared to the control meal.

Incorporating slower eating rates and lower energy density foods can significantly reduce caloric intake.

A fast-ER/high-ED increased energy intake by 19% compared to the control meal.

Fast eating rates and higher energy density foods can lead to increased caloric intake, which should be considered in dietary recommendations.

Semaglutide reduces percentage body weight by a mean difference of -10.73 (95% CI -12.24 to -9.21) at medium-term follow-up.

Semaglutide can be an effective treatment option for weight loss in adults with obesity.

Semaglutide increases the proportion of people achieving 5% weight loss with a risk ratio of 2.68 (95% CI 2.30 to 3.12) at medium-term follow-up.

Semaglutide may significantly help adults with obesity achieve clinically relevant weight loss.

Discontinuation of GLP-1 receptor agonists can lead to rapid weight regain and loss of cardiometabolic benefits.

Maintaining adherence to GLP-1 RA therapy is crucial for sustained weight loss and health benefits.

UPFs increase the risk of chronic diseases and death.

Public health initiatives should address the risks associated with UPF consumption.

A 3-month regimen of nutrition counseling and high-intensity resistance training resulted in a 6.6% reduction in body fat and a 1.4% increase in muscle mass.

Practitioners can implement similar exercise and nutrition regimens to promote fat loss and muscle gain in breast cancer patients.

All groups demonstrated improvements in the measured outcomes.

Resistance training is effective for improving strength and muscle outcomes in females.

Patient-delivered lifestyle intervention yielded significantly less weight regain than standard-of-care (SOC) at month 18 (0.77 kg vs 2.37 kg; P = .002).

Patient-delivered interventions may be a viable alternative for weight loss maintenance.

Patient-delivered intervention showed parallel improvements in diastolic blood pressure, heart rate, physical activity, and sedentary behavior compared to SOC.

Improving cardiovascular metrics can enhance overall health in weight maintenance programs.

Semaglutide led to a mean relative weight loss of 13.3 ± 11.3% after 12 months in adults with type 1 diabetes.

Practitioners can consider semaglutide as an effective option for weight management in overweight/obese patients with type 1 diabetes.

Initiation of semaglutide was significantly associated with a -3.8% reduction in weight at 13 to 24 months.

Semaglutide may be an effective option for weight management in adults.

The appropriate use of NB-ER should consider the specific characteristics and adiposity-related complications of an individual.

Practitioners should assess individual patient characteristics when prescribing NB-ER.